Kuppens GZ, Ruiz MAD, van Dijk MJ, Rab MA, Derichs C, Saes J, Rijneveld AW, Cnossen MH, Nur E, Biemond BJ, Bartels M, Saraf SL, van Beers EJ. Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study. haematol [Internet]. 2020Sep.10 [cited 2026Mar.4];. Available from: https://haematologica.org/article/view/13179